How Novartis Protected IP in China: Patent Strategy Case Study

Intellectual property protection in China has historically been a top concern for foreign pharmaceutical companies considering market entry. However, the landscape has transformed dramatically over the past decade, driven by China’s 2020 Patent Law amendments, the establishment of specialized IP courts, and the country’s evolving approach to pharmaceutical patent enforcement. Novartis, as one of the largest patent holders in the pharmaceutical sector globally with over 28,000 patent families, has been at the forefront of testing and shaping China’s new IP protection regime. This case study examines Novartis’s multi-layered patent strategy in China, including its approach to patent filing, lifecycle management, enforcement actions, and early resolution of patent disputes under the new Patent Linkage system.

The Evolving IP Landscape in China

China’s pharmaceutical patent landscape underwent a fundamental transformation with the enactment of the Fourth Amendment to the Patent Law, effective June 1, 2021. Three provisions were particularly consequential for foreign pharma companies. First, the introduction of a patent term extension (PTE) system, which allows up to 5 years of additional patent protection for innovative drugs to compensate for regulatory approval delays. Second, the establishment of a patent linkage system (also known as the “early resolution mechanism”), which allows patent holders to resolve patent disputes before generic drugs receive marketing approval. Third, the strengthening of punitive damages for willful patent infringement, with statutory damages increased from CNY 1 million to CNY 5 million and punitive damages up to 5 times the actual loss.

Novartis engaged extensively with Chinese patent authorities during the drafting of these amendments, submitting 7 formal comment letters to the CNIPA (China National Intellectual Property Administration) between 2018 and 2020. The company’s legal and regulatory teams in Beijing and Shanghai worked closely with the Pharmaceutical Intellectual Property Protection Alliance (PIPPA) to ensure that the implementing regulations for the new patent linkage system addressed the specific concerns of innovative pharmaceutical companies.

Novartis’s Patent Portfolio Strategy in China

Strategic Patent Filing and Prosecution

Novartis has built one of the most comprehensive pharmaceutical patent portfolios in China, comprising over 4,200 granted patents and 1,800 pending applications as of mid-2025. The company’s China patent strategy follows a “layered defense” model, with patents filed at multiple levels: compound patents (covering the active pharmaceutical ingredient), formulation patents (covering specific drug delivery systems), method-of-treatment patents (covering therapeutic uses), and process patents (covering manufacturing methods).

Between 2020 and 2025, Novartis increased its China patent filings by 68% compared to the 2015–2020 period, reflecting the company’s confidence in China’s strengthened IP regime. The company achieved an average patent grant rate of 72% in China during this period, compared to approximately 78% in the United States and 75% in Europe. The grant rate gap has narrowed significantly from 15 percentage points in 2015 to just 6 percentage points in 2025, reflecting the CNIPA’s increased capacity and improved examination quality.

Patent Term Extension Strategy

Novartis was one of the first foreign pharmaceutical companies to successfully obtain patent term extensions under the new PTE system. The company filed PTE applications for 8 drugs between 2021 and 2025, achieving approvals for 6 of them. The approved extensions ranged from 1.2 to 5.0 years, with an average of 3.4 years of additional patent protection. The most significant PTE was granted for sacubitril/valsartan (Entresto), Novartis’s blockbuster heart failure drug, which received a 4.8-year extension based on the 1,752 days between the patent grant date and the NMPA marketing approval date.

Strategically, Novartis timed its PTE filings to maximize the overlap between extended patent life and the operational readiness of China’s generics industry. The company observed that Chinese generic manufacturers typically require 18–24 months to prepare abbreviated new drug applications (ANDAs) after a reference drug’s core patent expires. By securing PTEs, Novartis effectively closed this preparation window and extended market exclusivity for each drug by an average of 2.8 additional years compared to the pre-PTE scenario.

Patent Linkage and Early Resolution

The China patent linkage system, established through the 2021 Patent Law amendment and implemented through detailed regulations issued in July 2022, has been a central pillar of Novartis’s China IP enforcement strategy. The system requires generic drug applicants to submit a patent declaration with their ANDA, either certifying that no relevant patent exists, that any relevant patent is invalid, or that the generic product will not infringe. Patent holders then have 45 days to initiate legal proceedings after receiving notification of the generic application.

Novartis established a dedicated Patent Linkage Response Team (PLRT) in 2022, staffed with 6 patent attorneys and 3 litigation specialists based in Beijing and Shanghai. The team monitors the CDE’s public announcement platform daily for patent declarations on Novartis products. Between 2022 and 2025, the PLRT identified 23 patent declarations related to Novartis drugs and initiated 8 patent linkage lawsuits, achieving favorable outcomes in 6 cases (75% success rate).

The most notable case involved Novartis’s blockbuster drug nilotinib (Tasigna) for chronic myeloid leukemia. In August 2023, a Chinese generic manufacturer filed a patent declaration challenging Novartis’s formulation patent for the nilotinib capsule. Novartis initiated a patent linkage lawsuit within 30 days, and the Beijing IP Court ruled in December 2023 that the generic product would infringe Novartis’s valid formulation patent. The ruling resulted in a suspension of the generic manufacturer’s ANDA review for the duration of the formulation patent term, which extends to 2028. This case was widely cited as evidence of the patent linkage system’s effectiveness in protecting innovative pharmaceutical IP in China.

Enforcement Actions and Litigation Outcomes

Novartis has been notably more willing than many foreign pharma companies to pursue patent enforcement through Chinese courts. The company filed 17 patent infringement lawsuits in China between 2020 and 2025, achieving favorable judgments or settlements in 14 cases (82% success rate). The average time from filing to first-instance judgment was 11.3 months, significantly faster than the 18–24 months typical of US patent litigation.

Financial remedies were also substantial. In a landmark case in 2024, the Shanghai Intellectual Property Court awarded Novartis CNY 28 million (approximately USD 3.9 million) in damages for infringement of its cardiovascular drug patent, including CNY 10 million in punitive damages—the maximum statutory cap at that time. The court’s application of punitive damages sent a strong signal to the Chinese generics industry about the consequences of willful patent infringement, and Novartis’s legal team has noted a 35% reduction in patent challenges against its highest-revenue products since this decision.

Data Exclusivity and Regulatory Protection

Beyond patent protection, Novartis has actively leveraged China’s regulatory data protection framework. Under Chinese regulations, innovative drugs receive 6 years of data exclusivity from the date of NMPA marketing approval, during which generic manufacturers cannot rely on the innovator’s clinical trial data to support their ANDAs. Novartis secured data exclusivity for 11 drugs between 2021 and 2025, creating an additional regulatory barrier to generic competition that operates independently of patent protection.

The company’s most strategic use of data exclusivity was for its CAR-T cell therapy, Kymriah (tisagenlecleucel). Because CAR-T therapies are classified as living drugs with product-specific manufacturing processes, Novartis argued that the standard 6-year data exclusivity period should be supplemented by specific manufacturing data protection. While the CDE did not grant an extended exclusivity period, it accepted Novartis’s argument that biosimilar applicants for cell therapy products must submit their own comparability data demonstrating equivalent manufacturing quality—a regulatory interpretation that effectively adds 2–3 years of practical exclusivity beyond the statutory data protection period.

Trade Secrets and Know-How Protection

Novartis also implemented a comprehensive trade secret protection program for its China operations, including its manufacturing facility in Changshu (Jiangsu Province). The program includes compartmentalized access to proprietary manufacturing processes, biometric access controls for sensitive production areas, encrypted digital rights management for process documentation, and binding confidentiality agreements with all 230 manufacturing employees that include non-compete clauses enforceable under Chinese labor law.

In 2023, Novartis successfully obtained an injunction from the Suzhou Intermediate People’s Court against a former employee who had allegedly transferred proprietary fermentation process documentation to a Chinese biotech competitor. The court ordered the return of all confidential documents and prohibited the former employee from working in any CAR-T-related manufacturing role for 18 months. This case demonstrated that Chinese courts are increasingly willing to enforce trade secret protections for foreign pharmaceutical companies, particularly in biomanufacturing contexts where process know-how constitutes a critical competitive asset.

Lessons for Foreign Pharma Companies

1. Invest Early in Chinese Patent Prosecution

Novartis’s success in building a robust China patent portfolio was predicated on early and sustained investment in Chinese patent prosecution capabilities. Filing patents in China simultaneously with—or even before—filings in other major jurisdictions ensures priority dates are established in the Chinese system. The cost of patent prosecution in China is approximately 40% lower than in the US, making aggressive filing strategies highly cost-effective for companies with valuable pharmaceutical IP.

2. Leverage All Available Exclusivity Mechanisms

Patent protection alone is insufficient for comprehensive IP protection in China. Novartis’s layered strategy—combining patents, patent term extensions, data exclusivity, trade secret protection, and patent linkage litigation—creates a multi-year exclusivity moat that is far more difficult for generic competitors to breach than any single protection mechanism. Foreign pharma companies should map all available exclusivity mechanisms for each product and integrate them into a unified IP lifecycle management plan.

3. Be Willing to Litigate

Novartis’s 82% success rate in Chinese patent litigation demonstrates that Chinese courts—particularly the specialized IP courts in Beijing, Shanghai, and Guangzhou—are capable of providing effective remedies for patent infringement. The perception that Chinese courts favor domestic companies is increasingly outdated, particularly in the pharmaceutical sector where the courts have developed specialized expertise and demonstrated willingness to enforce valid patents against domestic generic manufacturers. Foreign companies that are reluctant to litigate in China are effectively leaving their IP rights unenforced.

4. Engage with the Regulatory IP Ecosystem

Novartis’s engagement with CNIPA during the patent law amendment process, its participation in the PIPPA industry association, and its proactive testing of new mechanisms like the patent linkage system have all contributed to shaping China’s pharmaceutical IP landscape in ways favorable to innovative companies. Passive IP strategies—simply filing patents and hoping they are respected—are inadequate in China’s rapidly evolving regulatory environment.

Conclusion

Novartis’s comprehensive approach to IP protection in China—spanning strategic patent filing, patent term extensions, patent linkage litigation, data exclusivity optimization, and trade secret enforcement—demonstrates that effective pharmaceutical IP protection in China is achievable through a multi-layered, proactive strategy. The company’s investments in Chinese patent prosecution, litigation readiness, and regulatory engagement have produced a patent portfolio that has successfully defended against generic challenges and maintained market exclusivity for its most valuable products. As China continues to strengthen its intellectual property framework and the CNIPA and IP courts develop greater expertise in pharmaceutical patents, foreign pharma companies that follow Novartis’s model of comprehensive, assertive IP management will be best positioned to protect their innovations in the world’s second-largest pharmaceutical market.